Navigation Links
Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
Date:11/26/2007

, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection in the U.S. and India with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the results from the co-infected HCV/HIV clinical trial will not be consistent with the results from the company's prior HCV clinical trials or preclinical studies and the risk that bavituximab will not be as effective as the current standard of care for co-infected patients. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products, as all of our products are currently in development; preclinical s
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014  CVS Caremark Corporation (NYSE: ... Tuesday, August 5, 2014, at 8:30 a.m. (EDT) with ... financial results. An audio webcast of the ... Relations portion of the CVS Caremark website for all ... . This webcast will be archived and available on ...
(Date:7/25/2014)... , July 25, 2014 Cardinal Health will ... pharmacies as winners of its prestigious Independent Pharmacy Best ... , one of the nation,s largest gatherings of independent ... – family-owned pharmacies from Ohio , ... – were selected for implementing exceptionally creative ...
(Date:7/25/2014)... 25, 2014 According to a ... and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, ... Growth, Trends and Forecast (Value and Volume), 2013 - ... 19.99 billion in 2012 and is expected to grow ... to reach USD 32.24 billion in 2019. ...
Breaking Medicine Technology:Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 2Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 4Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 5Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 6Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
... 18, 2011 Amarin Corporation plc (Nasdaq: AMRN ... disease, today reported positive, statistically significant top-line results from its ... Phase 3 trial met its primary and secondary efficacy endpoints ... The purpose of the ANCHOR trial was ...
... a speech delivered Wednesday, President Obama outlined a framework ... the President discussed Medicare and his proposals to decrease ... proposals is to "speed generic brands of medicine onto ... to his continued call to reduce the length of ...
Cached Medicine Technology:Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 2Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 3Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 4Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 5Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 6Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 7Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 8BIOCOM Response to Health Portion of President's Speech at George Washington University 2
(Date:7/27/2014)... analysis of hepatitis E virus (HEV) transmission by blood ... England have HEV in their plasma. The findings, published ... HEV-containing blood components (eg, red cells, platelets, and fresh ... in England. , The study retrospectively screened 225 ... between Oct, 2012 and Sept, 2013 for HEV RNA. ...
(Date:7/27/2014)... 2014 The report, “Glass Fiber ... By Raw Material, By Manufacturing Process, By Application ... By Geography – Global Trends & Forecast to ... market with an analysis and forecast by value ... and 107 figures spread through 347 slides and ...
(Date:7/27/2014)... medication to treat asthma and pneumonia can become ineffective. , ... drugs widely used to treat lung diseases work with the ... is caused by an infection, affects around 1 in 1000 ... children, the elderly, smokers and those with an underlying health ... UK are affected by asthma and the NHS spends around ...
(Date:7/27/2014)... Over the past five years, the ... well, thanks to many consumers valuing the taste and ... Coffee Association of Canada's Canadian Coffee Drinking Study in ... coffee per day. “This trend, coupled with many studies ... drinking tea on a daily basis, has stimulated consumer ...
(Date:7/27/2014)... 27, 2014 The report, “Oil Filter ... LCVs & HCVs), Market Type (OE & Aftermarket), Filter ... & Geography - Industry Trends & Forecast to 2018”, ... filters market with analysis and forecasting of the global ... is estimated to reach a revenue of $6.1 billion ...
Breaking Medicine News(10 mins):Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 3Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 4Health News:Drugs used to treat lung disease work with the body clock 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5
... U.S. households where English is not the primary language ... Medical Center researcher has found. , In a study ... Dr. Glenn Flores, professor of pediatrics at UT Southwestern ... of Children,s Health to examine whether disparities exist for ...
... BEDFORD, Mass., June 10 Insulet Corporation,(the "Company") (Nasdaq: ... a private,offering of $75 million in aggregate principal amount ... qualified institutional buyers in,reliance on Rule 144A under the ... the initial purchasers an option to purchase up to ...
... cardiac,arrest is a leading cause of death in ... it is imperative that every school develop an,emergency ... need to respond,effectively to children and adults who ... CPR and use an automated external defibrillator,(AED) are ...
... ,Best of Healthcare Furniture, ... Category for Third Straight ... by,Steelcase won the Gold Award in the Healthcare Furniture ... state-of-the-art product,design, technological innovation and environmental sustainability., (Photo: ...
... to kill cancer cells offer a promising strategy for ... body,s natural defenses often eliminate the viruses before they ... study by researchers at the Ohio State University Comprehensive ... improve this therapy for brain cancer patients. , The ...
... Snowe,(R-ME), member of the Senate Finance Committee, has ... pharmacy-related provisions to provide,prompt payment of Medicare Part ... Medicaid reimbursement cuts for generic prescription,drugs. In response, ... in,Camden, ME and a member of the National ...
Cached Medicine News:Health News:Children in non-English-speaking households face many health disparities, researcher concludes 2Health News:Insulet Corporation Announces Pricing of $75 Million of Convertible Senior Notes 2Health News:Insulet Corporation Announces Pricing of $75 Million of Convertible Senior Notes 3Health News:Statement of Robert O'Connor, M.D., M.P.H. Chair, American Heart Association, Emergency Cardiovascular Committee, on U.S. House of Representatives Passage of the Josh Miller HEARTS Act 2Health News:Three-peat: Nurture(R) Strikes Gold Again at NeoCon 2Health News:Cancer-killing viruses influence tumor blood-vessel growth 2Health News:Maine Community Pharmacy Owner Thanks Sen. Snowe for Supporting Inclusion of Common-Sense Reimbursement Provisions in Medicare Bill 2
... Shoulder Instrument Systems offer the ... and mini-open shoulder repairs, such ... repair. Smith & Nephew shoulder ... facilitate an easier and more ...
... Mini-Open Rotator Cuff Repair System facilitates ... time, incision size and the likelihood ... rotator cuff repair systems and implants. ... of matched cortical gauge punches, circular ...
Portal accessory instrument set. Set also includes a package of 8 mm Guide Wires (.15 cm x 38 cm), and Sterilization Tray....
... The Blitz Suture Retriever is for arthroscopic and ... of design eliminates complicated procedural steps. It ... of suture material and in conjunction with,anchors or ... A small, curved needle tip permits the placement ...
Medicine Products: